🇺🇸 FDA
Pipeline program

Low-dose rtPA

X11-0123

Phase 3 small_molecule completed

Quick answer

Low-dose rtPA for Ischemic Stroke is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Ischemic Stroke
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials